Shares of Orchard Therapeutics PLC – (NASDAQ:ORTX) have been given an average rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $26.20.
Several equities research analysts have recently weighed in on the company. Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Orchard Therapeutics in a research report on Monday, December 2nd. Zacks Investment Research cut Orchard Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, ValuEngine raised Orchard Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 6th.
In related news, insider Fmr Llc sold 19,721 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.49, for a total value of $266,036.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Several hedge funds and other institutional investors have recently modified their holdings of ORTX. Citigroup Inc. acquired a new position in Orchard Therapeutics during the fourth quarter worth $42,000. Lindbrook Capital LLC raised its stake in Orchard Therapeutics by 40.0% during the fourth quarter. Lindbrook Capital LLC now owns 3,500 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares in the last quarter. Fred Alger Management LLC acquired a new position in Orchard Therapeutics during the fourth quarter worth $69,000. Marshall Wace North America L.P. acquired a new position in Orchard Therapeutics during the fourth quarter worth $105,000. Finally, Trexquant Investment LP acquired a new position in Orchard Therapeutics during the fourth quarter worth $151,000. Institutional investors and hedge funds own 67.55% of the company’s stock.
ORTX opened at $12.60 on Friday. Orchard Therapeutics has a 1-year low of $9.78 and a 1-year high of $21.64. The company has a current ratio of 8.88, a quick ratio of 8.88 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.23 and a beta of -0.99. The business has a 50 day moving average of $13.65 and a 200-day moving average of $13.10.
About Orchard Therapeutics
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Read More: What does a market perform rating mean?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.